The Friedrich Miescher Institute for Biomedical Research (FMI), based in Basel, Switzerland, is a world class biomedical research institute dedicated to understanding the molecular mechanisms of health and disease. It is named after Friedrich Miescher, the Basel biochemist who discovered nucleic acids in 1869 – just over 100 years before the establishment of the FMI in 1970. The FMI has been playing a leading role in biomedical research for half a century.
With a staff of about 350 – representing 45 nationalities – and 23 research groups, the FMI’s main areas of focus are neurobiology, quantitative biology and epigenetics. In addition, the institute has set up strong technology platforms enabling ambitious, interdisciplinary research, and allowing staff to be trained in the use of state-of-the-art technologies. The FMI has gained international recognition as a center of excellence in innovative biomedical research.
Training young scientists – graduate students and postdoctoral fellows – is also part of the mission of the FMI. Our PhD and MD-PhD programs attract top international students. The institute is affiliated with the University of Basel, where most of our graduate students are enrolled and where many of our group leaders are employed as professors.
The FMI is also affiliated with the Novartis Institutes for BioMedical Research (NIBR). Our institute receives generous core funding from Novartis, our researchers are involved in numerous collaborations with colleagues at Novartis and Novartis has first right of refusal on intellectual property originating from the FMI. Funding is supplemented by competitive grants and fellowships from national and international funding agencies. We are proud of the fact that many FMI group leaders have been awarded prestigious ERC grants, and that over 20% of postdocs are recipients of an EMBO, HFSP or Marie Curie fellowship.
The FMI was led by Professor Susan Gasser from 2004 to 2019 and is currently led by Co-directors Professor Silvia Arber and Professor Dirk Schübeler.